| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 1306 |
| 1 | BEVACIZUMAB | 961 |
| 2 | PREDNISONE | 758 |
| 3 | METHOTREXATE SODIUM | 461 |
| 4 | DEXAMETHASONE | 440 |
| 5 | DEXAMETHASONE 1.5 MG | 439 |
| 6 | METHOTREXATE | 421 |
| 7 | INFLIXIMAB | 396 |
| 8 | RITUXIMAB | 394 |
| 9 | CYCLOPHOSPHAMIDE | 379 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ENALAPRILAT | 14 | 0.0551 |
| 1 | IBUPROFEN LYSINE | 25 | 0.0439 |
| 2 | BEVACIZUMAB-BVZR | 12 | 0.0170 |
| 3 | BERACTANT | 5 | 0.0136 |
| 4 | ISOFLURANE | 26 | 0.0132 |
| 5 | INFLIXIMAB-DYYB | 45 | 0.0131 |
| 6 | ZIV-AFLIBERCEPT | 13 | 0.0100 |
| 7 | VANCOMYCIN HYDROCHLORIDE | 72 | 0.0086 |
| 8 | METHYLNALTREXONE BROMIDE | 13 | 0.0086 |
| 9 | SORBITOL | 5 | 0.0083 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 1817 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1024 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 919 |
| 3 | Platinum-based Drug [EPC] | 764 |
| 4 | Tumor Necrosis Factor Blocker [EPC] | 687 |
| 5 | Nucleoside Metabolic Inhibitor [EPC] | 679 |
| 6 | Proton Pump Inhibitor [EPC] | 473 |
| 7 | Alkylating Drug [EPC] | 467 |
| 8 | Folate Analog Metabolic Inhibitor [EPC] | 466 |
| 9 | Benzodiazepine [EPC] | 417 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Farnesyltransferase Inhibitor [EPC] | 1 | 0.0128 |
| 1 | Gamma Secretase Inhibitor [EPC] | 6 | 0.0065 |
| 2 | Surfactant [EPC] | 7 | 0.0060 |
| 3 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1024 | 0.0055 |
| 4 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 20 | 0.0049 |
| 5 | CTLA-4-directed Blocking Antibody [EPC] | 231 | 0.0048 |
| 6 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 30 | 0.0047 |
| 7 | Interferon gamma Blocker [EPC] | 1 | 0.0042 |
| 8 | Medium-chain Triglyceride [EPC] | 2 | 0.0036 |
| 9 | Melanocortin 4 Receptor Agonist [EPC] | 1 | 0.0035 |